Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression

Siddhant U. Jain,Sima Khazaei,Dylan M. Marchione,Stefan M. Lundgren,Xiaoshi Wang,Daniel N. Weinberg,Shriya Deshmukh,Nikoleta Juretic,Chao Lu,C. David Allis,Benjamin A. Garcia,Nada Jabado,Peter W. Lewis
DOI: https://doi.org/10.1073/pnas.2006076117
IF: 11.1
2020-10-16
Proceedings of the National Academy of Sciences
Abstract:Significance A high frequency of missense mutations was recently discovered at histone H3.3 glycine 34 in 92% of giant cell tumors of the bone and 17% of high-grade astrocytomas. The molecular mechanism by which G34 mutations drive these tumors remains unclear. Here, we demonstrate that the G34-mutated “oncohistones” misregulate the negative cross-talk between two histone methyltransferase enzymes, Polycomb Repressive Complex 2 (PRC2) and SETD2. G34 mutations uniquely promote PRC2 activity by blocking SETD2-mediated H3K36 methylation at active enhancers and drive a gene expression program that enhances tumor growth. We propose that G34 oncohistones exploit the regulatory mechanisms that fine tune PRC2 activity in human malignancies.
multidisciplinary sciences
What problem does this paper attempt to address?
### What problems does this paper attempt to solve? This paper aims to explore how missense mutations at the G34 site in the H3.3 histone variant (such as G34W, G34R, etc.) promote tumorigenesis and development by changing the chromatin modification pattern. Specifically, the research focuses on how these mutations affect the activities of specific histone - modifying enzymes, especially the roles of Polycomb Repressive Complex 2 (PRC2) and the SETD2 enzyme. #### Main problems and research background 1. **High - frequency H3.3 G34 mutations**: - In a variety of childhood gliomas and bone tumors, missense mutations at the G34 site of the H3.3 histone have been found in approximately 92% of giant cell bone tumors (GCTB), 17% of high - grade astrocytomas (HGA), and 5% of osteosarcomas. 2. **Unclear mechanism**: - Although the existence of these mutations has been widely reported, the specific molecular mechanism remains unclear. In particular, the mechanism by which these mutations drive tumor development has not been fully elucidated. #### Main findings of the research 1. **G34 mutations affect SETD2 - mediated H3K36 methylation**: - G34 mutations will impede the methylation of the SETD2 enzyme at the H3K36 site without affecting the functions of the NSD1/2 enzymes. This leads to a decrease in the level of H3K36me3. 2. **Enhanced PRC2 activity**: - The decrease in the level of H3K36me3 promotes an abnormal increase in PRC2 - mediated H3K27me2/3 and reduces the level of H3K27ac. This change occurs at active enhancers with SETD2 activity. 3. **Altered gene expression profile**: - This altered histone modification pattern supports a unique gene expression profile that enhances tumor development in vivo. Specifically, it is manifested as an increase in the expression of pro - inflammatory genes related to early osteoblast differentiation. #### Conclusion The authors propose that H3.3 G34 mutations selectively promote PRC2 activity by interfering with SETD2 - mediated H3K36 methylation, thereby silencing enhancers involved in cell differentiation, which may be a potential mechanism by which these mutations drive tumor development. ### Summary The core problem of this paper is to reveal how H3.3 G34 mutations promote tumorigenesis by changing the local chromatin modification pattern. Research shows that these mutations promote an increase in PRC2 - mediated H3K27me2/3 by blocking SETD2 - mediated H3K36 methylation, ultimately resulting in a unique gene expression profile favorable for tumor growth.